New Delhi, The Indian Pharmaceutical Alliance (IPA) on Wednesday said tariffs alone will not help build a sustainable generic drug manufacturing base in the US, asserting that broader reforms are needed to ensure fair pricing, supply chain stability and long-term investments in the sector.
The IPA, comprising 23 leading Indian research-based generic pharmaceutical companies, issued this statement following US President Donald Trump's announcement that imported generic drugs will remain tariff-free for two years before tariffs rise to 100 per cent and 200 per cent later.
